Ligandrol (LGD-4033) and the mind: mood, sleep, anxiety

Ligandrol is considered one of the strongest SARMs: in studies, noticeable changes in body composition occurred even at a dose of 1 mg per day. It is precisely this potency that makes the question of its effect on the mind important. The editorial team has examined what is known about mood, sleep and anxiety while taking ligandrol, why the period after discontinuation is the most vulnerable, and what role the psychological factors that push people toward SARMs play.

What the clinical data say

The main controlled study of ligandrol in humans is the work of Basaria and colleagues (2013), in which 76 healthy young men received LGD-4033 at doses of 0.1–1 mg or placebo for 21 days. No serious adverse events were recorded, and the authors did not describe any psychiatric events that stood out against placebo.

However, as with other SARMs, the mind was not the subject of a dedicated assessment. The study did not use scales for depression, anxiety, aggressiveness or sleep quality. Three weeks of observation is too short a period to assess delayed effects, especially those that may occur after discontinuation.

The phase II study in patients after hip fracture (VK5211) was conducted in elderly people, whose psychological profile and motivation are entirely different from those of young people who train. Detailed data on mental effects from this program are scarce in the public domain.

The only source of data on "real-world" use is surveys of SARM users, in which respondents reported mood changes among the adverse effects (Efimenko et al., 2022). Such data do not allow a causal relationship to be established, but they indicate that the problem is not imaginary.

Powerful suppression and the "crash" after discontinuation

The most substantiated mechanism for ligandrol's effect on the mind is hormonal. In the Basaria study, even at a dose of 1 mg per day, total and free testosterone, SHBG and FSH declined within three weeks. For a drug used at such a low dose, this indicates a powerful effect on the hypothalamic-pituitary axis.

While ligandrol circulates in the blood, it partly compensates for androgenic action in the muscles. However, it does not aromatize, so it does not replace estradiol, which in men is important for libido, mood and well-being. Its long half-life (about 24–36 hours according to Basaria) means the drug accumulates and is eliminated gradually.

After discontinuation there comes a period when the SARM has already been cleared but the body's own testosterone has not yet recovered. It is precisely at this time that low mood, apathy, fatigue, decreased libido and irritability are most often described. This picture is well known for androgen-induced hypogonadism after steroids (Rahnema et al., 2014) and is biologically expected for potent SARMs.

The duration of recovery after ligandrol has not been studied. In the Basaria study, the values returned to normal after discontinuation, but this applies to three weeks of microdosing under medical supervision. For the longer cycles and higher doses seen in informal use, it is impossible to predict the recovery time.

Sleep, anxiety, irritability

There are no direct data on ligandrol's effect on sleep. Experience with androgens suggests that both their deficiency and their excess can affect sleep quality: for example, worsening of obstructive sleep apnea has been described with testosterone therapy. Whether this applies to SARMs is unknown.

Anxiety and irritability while taking SARMs often have a mixed origin. Some people take ligandrol together with stimulants, fat burners, large doses of caffeine and other androgens. In addition, products bought online frequently contain a different substance, or a different amount, than stated (Van Wagoner et al., 2017).

Aggressiveness deserves a separate mention. For anabolic steroids, controlled studies (Pope and Katz, 1994) recorded episodes of hypomania and aggressive behavior in some users. There are no such studies for SARMs, so the claim that ligandrol "does not affect aggression" is just as unfounded as the opposite.

In practical terms this means: if insomnia, anxiety or irritability appear while taking the drug, it is impossible to say with certainty what exactly caused them. That makes it all the more important not to ignore such changes and not to offset them with new substances.

Muscle dysmorphia and the risk of dependence

The mind is not only a consequence of use but often its cause. Many people who turn to SARMs are dissatisfied with their bodies and consider themselves insufficiently muscular, even when they objectively have well-developed musculature. This condition is described as muscle dysmorphia — a form of body dysmorphic disorder (Pope et al., 1997).

For people with muscle dysmorphia, any "rollback" of their form after a cycle is felt painfully. Combined with the hormonal "crash" after discontinuation, this creates a strong motivation to start using again in order to restore both well-being and appearance. This is how a cycle forms that is familiar to researchers of anabolic steroid dependence.

Androgen dependence is described as a distinct clinical phenomenon (Kanayama et al., 2009): people continue to use the substances despite negative consequences, experience withdrawal symptoms and cannot stop. Whether a similar dependence develops with SARMs has not been specifically studied, but the mechanisms — hormonal and psychological — are similar.

Signs that it is worth considering the role of psychological factors:

• constant dissatisfaction with the body despite objective progress;
• anxiety or panic over a missed workout or "imperfect" nutrition;
• repeated cycles despite side effects;
• worsening well-being each time after discontinuation and a desire to "go back";
• concealing use from loved ones and doctors.

How to assess your condition and when to seek help

If a person has taken or is taking ligandrol and notices changes in mood, sleep or behavior, it is worth seeing a doctor and speaking openly about all the substances involved. An endocrinologist or andrologist will assess the hormonal status: testosterone, LH, FSH, estradiol, SHBG, prolactin. At the same time, it is advisable to check liver values and a lipid panel.

When mood changes are persistent — lasting more than two weeks — or are accompanied by loss of interest in life, sleep disturbance or thoughts of hopelessness, a consultation with a psychiatrist or psychotherapist is needed. Thoughts of self-harm are grounds to seek help immediately, at the nearest emergency service.

Self-"treatment" of the hormonal crash with prescription drugs following forum protocols is not recommended: it adds risks and delays proper diagnosis.

If dissatisfaction with the body lies behind the use, working with a psychologist who understands body-image issues can be helpful. This is no less important than hormonal tests.

Editorial conclusions

There are no controlled data on ligandrol's effect on the mind: short clinical studies did not specifically assess mood, sleep and anxiety.

At the same time, ligandrol powerfully suppresses the hormonal axis even at microdoses, so the period after discontinuation — with a risk of low mood, apathy and decreased libido — is biologically expected.

Psychological factors — muscle dysmorphia, fear of losing form — can trigger repeated cycles and form a pattern resembling androgen dependence.

We also recommend reading our articles on the effect of ostarine on the mind, on the history of ligandrol's development, and on the comparison of the risks of ostarine and anabolic steroids.

References

1. Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87–95.
2. Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use: a controlled study of 160 athletes. Arch Gen Psychiatry. 1994;51(5):375–382.
3. Pope HG Jr, Gruber AJ, Choi P, Olivardia R, Phillips KA. Muscle dysmorphia: an underrecognized form of body dysmorphic disorder. Psychosomatics. 1997;38(6):548–557.
4. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966–1978.
5. Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.
6. Efimenko IV, Valancy D, Dubin JM, Ramasamy R. Adverse effects and potential benefits among selective androgen receptor modulators users: a cross-sectional survey. Int J Impot Res. 2022.
7. Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017;318(20):2004–2010.